Aspirin dalam Pencegahan Karsinoma Hepatoselular Terkait Infeksi Hepatitis B Kronis

Oleh :

dr. Hendra Gunawan SpPD-KKV

Berbagai studi telah menunjukkan manfaat aspirin dalam menurunkan risiko karsinoma hepatoselular (KHS) terkait infeksi hepatitis B kronis. KHS merupakan salah satu kanker yang menyebabkan mortalitas dan morbiditas signifikan. KHS sering ditemukan terkait dengan infeksi hepatitis B kronis. Selain hepatitis B, KHS juga berkaitan dengan hepatitis C, penyakit hati alkoholik, dan steatohepatitis nonalkoholik (NASH).[1]

Hingga saat ini, terapi antivirus seperti tenofovir merupakan salah satu pilar dalam tata laksana infeksi hepatitis B kronis. Penggunaan antivirus secara dini juga dilaporkan mampu menurunkan risiko KHS, namun tidak menghilangkannya. Oleh karena itu, penelitian terus dilakukan untuk mencari modalitas tata laksana lain yang dapat menurunkan risiko KHS pada infeksi hepatitis B kronis.[2,3]

Aspirin sudah dilaporkan bermanfaat sebagai kemoprofilaksis kanker kolorektal. Penelitian terbaru melaporkan bahwa penggunaan aspirin dosis rendah dapat menurunkan risiko kanker kolorektal. Saat ini, aspirin mulai diteliti manfaatnya dalam mencegah KHS.[4,5]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Perhimpunan Peneliti Hati Indonesia, Perhimpunan Dokter Spesialis Patologi Indonesia, Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia, Perkumpulan Subspesialis Radiologi Abdomen Indonesia, Perhimpunan Dokter Spesialis Bedah Digestif Indonesia. Epidemiologi dan Faktor Risiko Karsinoma Sel Hati. Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. 2017.
2. Wu C, Lin J, Ho H, Su C, Lee T, Wang S, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014;147(1):143-51.
3. Terrault N, Bzowej N, Chang K, Hwang J, Jonas M, American Association for the Study of Liver Diseases. AASLD Guidelines for treatment of chronic hepatitis B. Hepatology. 2018;67(4):1560-99.
4. Garcia Rodriguez L, Soriano-Gabarro M, Bromley S, Lanas A, Soriano L. New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case–control study in UK general practice. BMC Cancer. 2017;2017(17):637.
5. Coyle C, Cafferty F, Langley R. Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone? Current Colorectal Cancer Reports. 2016;2016(12):27-34.
6. Tsan Y, Lin M, Ho W, Chen P. Nucleoside analogues, Statins and the Risk of Hepatocellular Carcinoma In Patients With Hepatitis b Virus Infection. Value in Health. 2015;18(3):A193.
7. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, et al. Effect of Antiviral Treatment With Nucleotide/Nucleoside Analogs on Postoperative Prognosis of Hepatitis B Virus–Related Hepatocellular Carcinoma: A Two-Stage Longitudinal Clinical Study. Journal of Clinical Oncology. 2013;31(29):3647-55.
8. Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World Journal of Hepatology. 2015;7(13):1742-54.
9. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Hepatitis B. 2019.
10. Chen H, Cai W, Chu E, Tang J, Wong C-C, Wong S, et al. Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice. Oncogene. 2017;36(31):4415-26.
11. Lee T, Hsu Y, Tseng H, Yu S, Lin J, Wu M, et al. Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. JAMA Internal Medicine. 2019;2019(1):E1-8.
12. Simon T, Ma Y, Ludvigsson J, Chong D, Giovannucci E, Fuchs C, et al. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncology. 2018;4(12):1683-90.
13. Young S, Chau G, Lee I-C, Yeh Y-C, Huo T-L, Su C, et al. Aspirin is associated with low recurrent risk in hepatitis B virus-related hepatocellular carcinoma patients after curative resection. Journal of the Formosan Medical Association. 2020;119(1):218-29.
14. Petrick J, Sahasrabuddhe V, Chan A, Alavanja M, Beane-Freeman L, Buring J, et al. NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project. Cancer Prevention Research (Phila). 2015;8(12):1156-62.
15. Hwang I, Chang J, Kim K, Park S. Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. Scientific Reports. 2018;8(1):4968.
16. Simon T, Chan A. Reduced Hepatocellular Carcinoma Risk vs Bleeding Risk Associated With Aspirin—In Reply. JAMA. 2019;5(6):911-2.
17. Lee CH, Lee YB, Moon H, et al. Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B. Aliment Pharmacol Ther. 2023 Oct;58(7):704-714. doi: 10.1111/apt.17643.